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Abstract 
Background: Ipilimumab is an approved immunotherapy that has shown an overall survival benefit in patients with 
cutaneous metastatic melanoma in two phase III trials. As results of registrational trials might not answer all questions 
regarding safety and efficacy of ipilimumab in patients with advanced melanoma seen in daily clinical practice, the 
Dermatologic Cooperative Oncology Group conducted a phase II study to assess the efficacy and safety of ipili-
mumab in patients with different subtypes of metastatic melanoma.
Patients and methods: We undertook a multicenter phase II study in melanoma patients irrespective of location 
of the primary melanoma. Here we present data on patients with pretreated metastatic cutaneous, mucosal and 
occult melanoma who received up to four cycles of ipilimumab administered at a dose of 3 mg/kg in 3 week intervals. 
Tumor assessments were conducted at baseline, weeks 12, 24, 36 and 48 according to RECIST 1.1 criteria. Adverse 
events (AEs), including immune-related AEs were graded according to National Cancer Institute Common Toxicity 
Criteria (CTC) v.4.0. Primary endpoint was the OS rate at 12 months.
Results: 103 pretreated patients received at least one dose of ipilimumab, including 83 cutaneous, seven mucosal 
and 13 occult melanomas. 1-year OS rates for cutaneous, mucosal and occult melanoma were 38 %, 14 % and 27 %, 
respectively. Median OS was 6.8 months (95 % CI 5.3–9.9) for cutaneous, 9.6 months (95 % CI 1.6–11.1) for mucosal, 
and 9.9 months (lower 95 % CI 2.3, upper 95 % CI non-existent) for occult melanoma. Overall response rates for cuta-
neous, mucosal and occult melanoma were 16 %, 17 % and 11 %, respectively. Eleven patients had partial response 
(16 %) and ten patients experienced stable disease (14 %), none achieved a complete response. Treatment-related AEs 
were observed in 71 patients (69 %), including 20 grade 3–4 events (19 %). No new and unexpected safety findings 
were noted.
Conclusions: Ipilimumab is a treatment option for pretreated patients with advanced cutaneous melanoma seen in 
daily routine. Toxicity was manageable when treated as per protocol-specific guidelines.
Trial registration: Clinical Trials.gov NCT01355120
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Background
From a clinical like from a scientific perspective, the 
recent advances in cancer immunotherapy have been 
acknowledged as a major breakthrough [1]. Especially for 
melanoma patients, immune checkpoint inhibitors begin 
to witness an enormous therapeutic potential, resulting 
very recently in the approval of the first-in-class anti-pro-
grammed-death-receptor-1 (PD-1) inhibitors nivolumab 
and pembrolizumab for the treatment of unresectable or 
metastatic melanoma [2–5].
The cytotoxic T-lymphocyte-associated antigen-4 
(CTLA-4) inhibitor ipilimumab has been authorized 
for use in advanced, metastatic melanoma in the United 
States and in the European Union—as in many other 
countries worldwide since—on basis of two pivotal phase 
III studies [6, 7]. CTLA-4, a native regulator of T cell acti-
vation, downregulates T-cell function through a variety 
of mechanisms, and finally induces T-cell cycle arrest 
[8]. Because many of the immune checkpoints are regu-
lated by ligand-receptor interactions, CTLA-4 can be 
easily blocked by monoclonal antibodies or recombinant 
ligand-like proteins that block CTLA-4 as a negative reg-
ulator of immunity, hence enhancing natural antitumor 
immunity [9].
Serving as the first mechanistically defined immune 
checkpoint inhibitor, ipilimumab has been intensely 
investigated in clinical registrational trial settings [6, 7] 
in patients with cutaneous melanoma, the most frequent 
melanoma subgroup with morphological and molecular 
distinctions from other clinical disease subgroups [10]. 
However, results of registrational trials might not answer 
all questions regarding safety and efficacy of ipilimumab 
in advanced melanoma patient cohorts seen in daily 
routine.
Here we report the results of the open-label, multi-
center, single-arm phase II DeCOG trial to further eval-
uate the efficacy and safety of 3  mg/kg ipilimumab in 
pretreated patients with cutaneous, mucosal and occult 
metastatic melanoma seen in daily routine in interdisci-
plinary skin cancer units in Germany. Data for patients 
with ocular melanoma are reported elsewhere [11].
Patients and methods
Patients
Eligibility criteria included documented unresect-
able stage III or stage IV metastatic cutaneous, occult, 
mucosal and ocular melanoma according to American 
Joint Committee on Cancer cutaneous melanoma stag-
ing criteria [12]. Patients who had received at least one 
prior systemic therapy were eligible. Previous systemic 
treatment had to be completed ≥28  days before receiv-
ing ipilimumab. Additional requirements included 
age ≥18  years, Eastern Cooperative Oncology Group 
(ECOG) performance status ≤2, life expectancy of 
≥6  months (estimation of life expectancy was at the 
discretion of the participating investigators), measur-
able disease according to Response Evaluation Criteria 
In Solid Tumors (RECIST) 1.1 [13], adequate bone mar-
row, renal and hepatic function. Patients with a history of 
active autoimmune disease and chronic use of systemic 
corticosteroids were excluded. Patients with asymp-
tomatic, radiographically stable previously treated or 
untreated brain metastases were eligible.
Study design
This multicenter, open-label, phase II study (DeCOG-
MM-PAL11-Trial; CA184-137) was conducted in two 
parts. Part 1 of the study was open for recruitment from 
May 2011 to August 2011; in an Additional file 1: Figure 
S1 the patient flow is described. This part allowed recruit-
ment of pretreated melanoma patients irrespective of 
location of the primary melanoma. Part 2, which was only 
eligible for patients with pretreated or treatment-naïve 
metastatic ocular melanoma to allow for a valid analysis 
of this subgroup, was closed on September 30, 2012. Data 
from part 1 and 2 for patients with ocular melanoma 
are reported elsewhere [11]. Twenty-five Dermatologic 
Cooperative Oncology Group (DeCOG) skin cancer units 
in Germany participated. The study was approved by 
institutional ethics committee University Duisburg-Essen 
(approval number 10–4531) and the German compe-
tent authority Paul-Ehrlich-Institute (Langen, Germany, 
approval number 1233), and conducted in accordance 
with the Declaration of Helsinki/Good Clinical Practice. 
All patients gave written informed consent. The protocol 
for this trial is available as Additional file 2. Ipilimumab 
was administered intravenously over 90  min at a dose 
of 3  mg/kg every 3  weeks for a total of four infusions. 
Patients with progressive disease (PD) at ≥3  months 
from week 12 assessment following stable disease (SD), 
an initial partial (PR) or complete response (CR) were eli-
gible for re-induction with ipilimumab following at the 
same dosage. Dose reduction was not allowed, but skip-
ping of one dose of ipilimumab was recommended when 
adverse events (AE) occurred. Rapid disease progression, 
intolerable toxicity or patient withdrawal led to treatment 
discontinuation. The primary endpoint was the overall 
survival (OS) rate at 12 months.
Assessments
Regular assessments, including a physical examination 
and standardized blood testing, were carried out at base-
line and every 3 weeks during induction and re-induction 
phases. Tumor assessments were conducted at base-
line, weeks 12, 24, 36 and 48 using the RECIST version 
1.1 [13]. Adverse events (AEs) were graded according to 
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the National Cancer Institute Common Toxicity Crite-
ria (CTC version 4.0). All AEs were recorded from the 
time of the first ipilimumab administration until 70 days 
after treatment discontinuation. AEs were defined as an 
immune-related AE (irAE) if they were associated with 
drug exposure, consistent with an immune phenomenon 
and if other causes were ruled out. IrAE management 
was based on protocol-specific treatment algorithms. All 
AEs that were definitely, probably or possibly related to 
study drug were defined as related AEs.
Statistical methods
This report includes results based on the data cutoff of 
December 6, 2013. Patient and disease characteristics 
were analyzed using descriptive statistics. Categorical 
values were expressed as counts and percentage whereas 
continuous values were expressed as median and range 
values. OS was defined as the time from the first admin-
istration of ipilimumab to death from any cause. Patients 
last known to be alive were censored at the date of last 
contact. Progression-free survival (PFS) was defined as 
the time from the first dose of ipilimumab to the first 
date of documented progression as per RECIST, or date 
of death, whichever came first. Patients last known to 
be alive and progression-free were censored at the date 
of last contact. PFS rate at 6 months was defined as the 
proportion of patients being alive and without progress 
6  months after the first ipilimumab administration. 
Patients with unknown survival status or unknown sta-
tus of progression at 6  months were censored. The 1- 
and 2-year survival rates were defined as the proportion 
of patients being alive 12 or 24  months after their first 
ipilimumab administration. Patients with unknown sur-
vival status at 12 or 24 months were censored. OS, PFS, 
PFS rate at 6  months, 1- and 2-year survival rates were 
estimated by the Kaplan–Meier method. For medians of 
OS and PFS, 95 % confidence intervals (CIs) were calcu-
lated using the Brookmeyer and Crowley method. The 
log-rank test was used to compare the 1-year and 2-year 
OS rates in patients with cutaneous melanoma between 
several subgroups, i.e. the BRAF mutational status, the 
presence of brain metastases, the lactate dehydroge-
nase (LDH) level prior to receiving ipilimumab [<2-fold 
upper level norm (ULN) vs. ≥2× ULN], the number of 
ipilimumab doses (<4 vs. 4), and the absolute lympho-
cyte count (ALC) (<1000/µl vs. ≥1000/µl) before the first 
(week 1), the second (week 4) and the third dose (week 
7) of ipilimumab. Due to small sample sizes comparisons 
of 1-year and 2-year OS rates in patients with mucosal 
and occult melanoma were not done. Two sided p values 
were evaluated and a p value of <0.05 was considered sta-
tistically significant. All variables with significant differ-
ences between their stratifications regarding the overall 
survival were included in a multivariate Cox proportional 
hazards model. To determine potential predictors, all 
independent covariates (LDH, number of ipilimumab 
doses, ALC week 4, brain metastases), were entered into 
a backward Cox regression model for the overall survival. 
The stay level was p = 0.05. All covariates being still sig-
nificant were considered as potential predictors. For the 
hazard ratio, 95  % CIs were calculated using the Wald 
method. The overall response rate (ORR) was defined as 
the proportion of patients with PR and CR whereas the 
disease control rate (DCR) was defined as the propor-
tion of patients with CR, PR and SD. Lost to follow-up 
was documented if the patient did not respond to phone 
calls (3 times) and to a written invitation. Analyses were 




Between May to August 2011, 103 patients were enrolled 
and received at least one dose of ipilimumab, including 83 
patients with cutaneous melanoma, 13 with occult mela-
noma and seven with mucosal melanoma (Table 1). Base-
line patient characteristics are reported in Table  1. All 
103 patients had received previous systemic anti-cancer 
treatment, including chemotherapy, immunotherapy, and 
targeted agents (Table 1). The most common chemother-
apies were dacarbazine and carboplatin/paclitaxel given 
in 73 (71 %) and 30 (29 %) of all patients. None had previ-
ously received ipilimumab but 18 patients had undergone 
previous immunotherapy treatment with interferon α or 
vaccination. 31 patients presented with brain metastases 
at study entry, with similar proportions observed across 
the different melanoma subtypes (Table  1). Sixty-four 
patients (62  %) completed the induction phase, includ-
ing 52 patients with cutaneous, four with mucosal and 
eight with occult melanoma. Three patients with cutane-
ous melanoma experienced PR at week 12 and were re-
induced after 91, 232 and 217 days, respectively (Table 2). 
The median number of doses received in the induction 
phase was four (range 1–4). Among the 39 patients (38 %) 
who did not complete the induction phase, 11 (11  %) 
died, 16 (16 %) developed PD, eight (8 %) had intolerable 
AEs and four (4 %) withdrew their informed consent.
Efficacy
The 1-year rate for OS was 38  % (95  % CI 27–49) for 
cutaneous melanoma, 14 % (95 % CI 1–47) for mucosal 
melanoma, and 27  % (95  % CI 5–57) for occult mela-
noma. 2-year OS rates for cutaneous and occult mela-
noma were 22  % (95  % CI 13–33) and 27  % (95  % CI 
5–57), respectively. All of the patients with mucosal mel-
anoma died before month 24 after the first ipilimumab 
Page 4 of 11Zimmer et al. J Transl Med  (2015) 13:351 
Table 1 Baseline patient characteristics (n = 103 patients totally)
Patient characteristics Cutaneous melanoma Mucosal melanoma Melanoma of unknown 
primary
N % N % N %
No. patients, % 83 100 7 100 13 100
Age, years
Median (range) 63 (29–85) 63 (33–37) 62 (40–77)
Sex
Male 53 64 2 29 11 29
Female 30 36 5 71 2 71
ECOG baseline
0 51 61 2 29 12 92
1 23 28 5 71 1 8
2 9 11 – –
BRAF mutation
Not mutated 29 35 3 43 5 39
Mutated 17 21 – 6 46
Not known 37 45 4 57 2 15
Disease stage (all: Stage IV)
M1a 6 7 – 3 23
M1b 15 18 2 29 1 8
M1c 62 75 5 71 9 69
LDH
<2 ULN 67 81 5 71 11 85
≥2 ULN 16 19 2 29 2 15
Brain metastases
No 57 69 5 71 10 77
Yes 26 31 2 29 3 23
Prior systemic therapy in stage IV (except radiotherapy)
No – – –
Yes 83 100 7 100 13 100
Number of prior systemic therapies
1 42 51 6 86 8 62
2 27 33 – 3 23
≥3 13 16 1 14 2 15
Not applicable 1 1 – –
Immunotherapy
No 67 81 7 100 11 85
Yes 16 19 – 2 15
If yes, type of previous immunotherapy
Interferon alpha 11 13 – 2 15
Vaccination 5 6 – –
Kinase inhibitors
No 71 86 7 100 9 69
Yes 12 14 – 4 31
If yes, type of previous kinase inhibitor
BRAF inhibitor 7 8 – 2 15.5
MEK inhibitor 4 5 2 15.5
Chemotherapy
0 9 11 – 2 15
1 47 57 6 86 8 62
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administration. Six-month rate for PFS were 16 % (95 % 
CI 9–25) for cutaneous melanoma, 14 % (95 % CI 1–47) 
for mucosal melanoma, and 17  % (95  % CI 3–41) for 
occult melanoma. Median OS from the first dose of ipili-
mumab for cutaneous, mucosal and occult melanoma 
were 6.8 (95 % CI 5.3–9.9; Fig. 1a), 9.6 (95 % CI 1.6–11.1; 
Fig. 1b) and 9.9 (lower 95 % CI 2.3, upper 95 % CI non-
existent; Fig.  1c) months, respectively. Seventy of 103 
patients were evaluable for efficacy assessment (Table 3). 
Among the 33 patients (32 %) who were not assessable, 
22 died before the assessment of change in tumor burden 
(including 13 with brain metastases), three developed PD 
(including two with brain metastases), three had intol-
erable AEs, one had no measurable disease at baseline, 
three withdrew their informed consent (including one 
with brain metastases) and one was lost to follow-up. 
The DCR was 29 % for cutaneous, 50 % for mucosal and 
22  % for occult melanoma (Table  3). Overall response 
rates for cutaneous, mucosal and occult melanoma were 
16 %, 17 % and 11 %, respectively (Table 3). Among the 
70 patients evaluable for response, the overall response 
rate for 15 patients with brain metastases was 13  %: a 
response rate similar to the one found for the remaining 
55 patients without brain metastases (16  %). Of the 15 
patients with brain metastases seven patients had intrac-
ranial SD, seven intracranial PD and one patient expe-
rienced intracranial CR. In total, ten patients showed 
similar response pattern in intracranial and extracranial 
metastases and five patients had different response pat-
tern, e.g. in one patient an intracranial response (CR) was 
observed, unfortunately associated with extracranial PD 
(Additional file 3: Table S3). 
The 1-year OS rate was higher in patients with cuta-
neous melanoma who had no brain metastases (51  % 
vs. 12  %, p  <  0.0001, Fig.  2a), in patients with a LDH 
level <2× ULN (42 % vs. 19 %, p =  0.0007), in patients 
who received four ipilimumab doses (53  % vs. 14  %, 
p < 0.0001; Fig. 2b), and in patients with an ALC ≥1000/
µl before the second dose of ipilimumab (week 4) (47 % 
vs. 22  %, p  =  0.002; Fig.  2c). The apparent better OS 
observed in patients who received all four ipilimumab 
doses, could be solely based on a time dependent bias, 
as receiving four doses of ipilimumab required surviv-
ing >10 weeks after therapy initiation. This only applied 
to 39 % of the patients who received <4, but not surpris-
ingly all with four doses of ipilimumab. BRAF mutational 
status, the ALC before the first and the third dose of ipili-
mumab in patients with cutaneous melanoma were not 
associated with OS. In a multivariate analysis, the fac-
tors independently associated with better OS were the 
administration of four ipilimumab doses (e.g. patients 
with less than 4 doses were at higher risk of death; hazard 
ratio 4.3, 95 % CI 2.3–8.0), an ALC ≥1000/µl before the 
second dose of ipilimumab (week 4) (e.g. patients with 
ALC <1000/µl were at higher risk of death; hazard ratio 
2.0; 95 % CI 1.1–3.8), and the absence of brain metastases 
(e.g. patients with brain metastases were at higher risk of 
death; hazard ratio 1.9, 95 % CI 1.0–3.5).
Safety
Ninety-eight of 103 patients (95  %) experienced one 
or more AEs (Table  4). Treatment-related AEs were 
reported in 71 patients (69  %); 20 patients (19  %) had 
treatment-related grade 3 or 4 AEs. The majority of 
ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase
Table 1 continued
Patient characteristics Cutaneous melanoma Mucosal melanoma Melanoma of unknown 
primary
N % N % N %
 2 20 24 – 2 15
≥3 7 8 1 14 1 8
Table 2 Outcomes of patients with ipilimumab re-induction therapy
RECIST response evaluation criteria in solid tumors, PR partial response, SD stable disease, PD progressive disease
Age, 
years
Best response at week 
12 (RECIST)
Duration between 1st 






Best overall response 
after re-induction 
(RECIST)




74 PR 91 SD SD 17.1 Yes
56 PR 232 PR CR 25.5 Yes
73 PR 217 PD SD 24.8 Yes
Page 6 of 11Zimmer et al. J Transl Med  (2015) 13:351 
treatment-related AEs were irAEs, occurring in 52 
patients (51  %). Most common irAEs were gastrointes-
tinal disorders—diarrhea and colitis, skin-related toxic 
effects—pruritus and rash, and hepatic disorders—
increased alanine aminotransferases (ALT) and aspartate 
aminotransferases (Table  4). The most frequent grade 3 
or 4 irAEs were diarrhea and colitis, noted in ten (10 %) 
and 5 patients (5 %), respectively. There was one patient 
with a gastrointestinal perforation due to grade 3 colitis 
and diarrhea. After surgery and treatment with 2  mg/
kg methylprednisolone intravenous, diarrhea and colitis 
improved and corticosteroid therapy was tapered slowly 
over 6 weeks. Immune-related AEs were generally revers-
ible when managed as per protocol-specific treatment 
Fig. 1 Kaplan–Meier curves for 1-year overall survival (OS) rates of different melanoma subtypes. Pretreated patients with a metastatic cutaneous 
melanoma (1-year OS rate: 38 %), b mucosal melanoma (1-year OS rate: 14 %), and c occult melanoma (1-year OS rate: 27 %). All patients received 
ipilimumab 3 mg/kg
Table 3 Overall response rates (ORR) and disease control rates (DCR) (n = 70 patients totally)
CR complete response, PR partial response, RECIST response evaluation criteria in solid tumors, SD stable disease
Patients with measurable disease  
(and at least one tumor assessment)
Cutaneous melanoma Mucosal melanoma Melanoma 
of unknown  
primary
N % N % N %
No. patients  (%) 55 100 6 100 9 100
Response pattern (acc. to RECIST)
Complete response – – –
Partial response 9 16 1 17 1 11
Stable disease 7 13 2 33 1 11
Progressive disease 39 71 3 50 7 78
Best ORR (according to RECIST)
ORR (=CR + PR) 9 16 1 17 1 11
ORR at week 12 7 13 1 17 –
ORR at week 24 6 11 1 17 –
Best DCR (according to RECIST)
DCR (=CR + PR + SD) 16 29 3 50 2 22
DCR at week 12 15 27 3 50 2 22
DCR at week 24 10 18 1 17 1 11
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Fig. 2 Kaplan–Meier curves for overall survival (OS) of subgroups (pretreated patients with metastatic cutaneous melanoma). Subgroups were 
stratified as follows: by a the absence of brain metastases before the first dose of ipilimumab; Absence of brain metastases: median OS 12.3 months 
(95 % CI 6.0–19.4); brain metastases present: median OS 4.2 months (95 % CI 2.0–6.1); b the number of ipilimumab doses (4 versus <4); 4 doses: 
median OS 13.5 months (95 % CI 7.9–20.4); <4 doses: median OS 2.1 months (95 % CI 1.6–4.1); and c the absolute lymphocyte count (ALC) (≥1000/
µl versus <1000/µl) before the second dose (i.e. week 4) of ipilimumab; ALC ≥1000/µl: median OS 9.9 months (95 % CI 6.1–18.5); ALC <1000/µl: 
median OS 3.6 months (95 % CI 1.8–5.6)
Table 4 Reported adverse events in overall study population (n = 103 patients totally)
ir immune related, GI gastrointestinal, ALT alanine aminotransferases, AST aspartate aminotransferases, MUP melanoma of unknown primary
a Patients may have had more than one adverse event
b Other gastrointestinal disorders were abdominal pain (n = 6 grade 1/2; n = 3 grade 3/4), constipation (n = 1 grade 1/2) and elevated lipase (n = 1 grade 3/4)
Adverse events (AE)a Cutaneous melanoma Mucosal melanoma MUP Total
No. patients (%) 83 (100) 7 (100) 13 (100) 103 (100)
All grades Grade 3/4 All grades Grade 3/4 All grades Grade 3/4 All grades Grade 3/4
Patients with at least one AE 79 (95) 36 (43) 6 (86) 4 (57) 13 (100) 7 (54) 98 (95) 47 (46)
Patients with treatment-related AE 57 (69) 14 (17) 3 (43) 2 (29) 11 (85) 4 (31) 71 (69) 20 (19)
Patients with any irAE 40 (48) 12 (15) 2 (29) 1 (14) 10 (77) 4 (31) 52 (51) 17 (17)
irDermatitis 21 (25) – 1 (14) – 3 (23) – 25 (24) –
Pruritus 8 (10) – 1 (14) – 2 (15) – 11 (11) –
Rash 8 (10) – – – 1 (8) – 9 (9) –
Erythema multiforme 4 (5) – – – – – 4 (4) –
Hand-foot-syndrome 1 (1) – – – – – 1 (1) –
irGastrointestinal disorders 39 (47) 15 (18) 2 (28) 1 (14) 8 (62) 4 (31) 49 (48) 20 (20)
Colitis 6 (7) 4 (5) – – 1 (8) 1 (8) 7 (7) 5 (5)
Diarrhea 25 (30) 8 (10) 1 (14) 1 (14) 4 (31) 1 (8) 30 (29) 10 (10)
GI-perforation 1 (1) 1 (1) – – – – 1 (1) 1 (1)
Otherb 7 (9) 2 (2) 1 (14) – 3 (23) 2 (15) 11 (11) 4 (4)
irEndocrine disorders 5 (6) 1 (1) – – – – 5 (5) 1 (1)
Hypophysitis 4 (5) 1 (1) – – – – 4 (4) –
Hypothyroidism 1 (1) – – – – – 1 (1) –
irHepatic disorders 4 (5) 1 (1) – – – – 4 (4) 1 (1)
Increased ALT 1 (1) – – – – – 1 (1) –
Increased AST 1 (1) – – – – – 1 (1) –
Other 2 (2) 1 (1) – – – – 2 (2) 1 (1)
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guidelines. Most of the irAEs resolved with corticoster-
oid therapy. None of the patients required additional 
immunosuppression with infliximab or mycophenylate 
mofetil. Treatment related non-irAEs included anemia, 
fatigue, bone pain, fever, nausea and vomiting. There was 
no treatment-related death.
Discussion
This prospective DeCOG phase II trial evaluated the effi-
cacy and safety of ipilimumab in a cohort of 103 patients 
with 83 pretreated metastatic cutaneous, seven mucosal 
and 13 occult melanoma. The distribution rate of these 
clinical subgroups in our trial—considered as representa-
tive for a daily routine hospital setting—has been very 
similar to the rates reported for a named-patient program 
in Germany with approximately 200 patients [14] [Data 
not disclosed]. In both multi-center studies, patients with 
pretreated cutaneous melanoma represented approxi-
mately 80 % of all patients; patients with mucosal mela-
noma (DeCOG: 7  %; expanded access program (EAP) 
Germany: 5  %) and with occult melanoma (DeCOG: 
13 %; EAP Germany: 11 %) were enrolled less frequently. 
Very similar distribution rates were also reported from 
large EAPs with 3 mg/kg ipilimumab in Italy, Spain and 
Australia [15–17] (Additional file 4: Table S4), with rather 
constant percentages of mucosal melanoma patients 
(ranging from 7 to 8  %) and occult melanoma patients 
(6–8 %) enrolled.
The reported OS rate at 12 months of 38 % for patients 
with cutaneous melanoma is fitting with data from sev-
eral other studies (range 33–38  %) (Additional file  4: 
Table S4) enrolling daily clinical routine patients with 
a high portion of this melanoma subgroup [14–17]; a 
report on an EAP run in the Netherlands and the UK 
with cutaneous melanoma patients only also resulted into 
an 1-year OS rate of 38 % [18]. In a pivotal, randomized 
phase II dose-ranging study, in which patients with ocu-
lar and mucosal melanoma were excluded as well as 
patients with brain metastases, the OS rate at 12 months 
for the ipilimumab 3  mg/kg arm of a similar size was 
39 % [19]. 2-year survival rates in our study (22 %), in the 
Dutch-UK expanded access cohort (23 %) [18] and in the 
pivotal phase II study (24 %) [19] were very similar too: 
these rates also match with recently published data from 
a pooled analysis of long-term survival data from approx-
imately 5000 patients included in the ipilimumab pivotal 
clinical trials and the EAP [20]. This landmark analysis 
depicts a plateau in the iplilimumab survival curves at 
around 20 %.
Compared to skin melanoma, primary noncutaneous 
melanomas show a less favorable outcome when treated 
with 3 mg/kg ipilimumab. For occult and mucosal mela-
noma we found lower 1-year survival rates with 27 and 
14 %, respectively. Due to the very low patient numbers, 
the figures for mucosal melanoma are difficult to inter-
pret. However, similar findings were reported from the 
Australian EAP [17]—the only other study so far report-
ing OS outcomes for cutaneous versus noncutaneous 
melanoma treated with 3  mg/kg ipilimumab. Here, the 
median OS for cutaneous melanoma was twice as high 
(11.7 months) as for patients with uveal (5.7 months) or 
mucosal (5.8  months) melanoma. Again, the low num-
ber of patients with noncutaneous melanoma resulted 
into very huge confidence intervals. In the Italian EAP, 
a median OS of 6.4 months was reported for 71 patients 
with mucosal melanoma [21]—a value slightly below 
the 6.8  months reported for the overall patient collec-
tive of around 850 patients, 74  % of them with cutane-
ous melanoma [15]. However, survival data for cutaneous 
melanoma patients only were not reported from Italy. 
A retrospective case series from the US similarly found 
a median OS of 6.4  months for a cohort of 34 mucosal 
melanoma patients [22]. These estimates all remain 
below the median OS of 10–11  months, reported for 
primarily cutaneous melanoma patient collectives in the 
pivotal phase III trial with highly selected patients and 
a retrospective long-term-survival landmark analysis [6, 
20]. The observed OS difference may be explained by 
the acknowledged aggressive character of mucosal mela-
noma; this clinical subgroup represents distinct clinico-
pathological and molecular features linked with reduced 
survival rates [10, 21]. For the 13 patients with occult 
melanoma, data for comparison of efficacy are not avail-
able from other studies (Additional file 4: Table S4). Due 
to the small sample, the inconclusive outcomes in terms 
of median overall survival and 1-year survival rate do not 
allow any conclusion, although a better survival outcome 
for stage IV patients with nodal metastasis of melanoma 
from an unknown primary (MUP) versus melanoma 
from a known primary has been reported in a retrospec-
tive cohort study [23]. The relative high portion of occult 
melanoma patients in our initial study cohort, as com-
pared to literature [24, 25], is considered as a selection 
effect, because such patients usually cannot be included 
into clinical trials.
In our study, four doses of ipilimumab, the absence of 
brain metastases, and an ALC ≥1000/µl at week 4 were 
identified as factors independently associated with a 
better OS in the 83 patients with cutaneous melanoma. 
These findings enforce the current level of evidence 
gained by several studies that the completion of the 
four-dose-induction phase [14, 26], the absence of brain 
metastases [14–16], and high ALC counts and/or changes 
in ALC pharmacodynamics [16–18, 26–29] are predictive 
for a significant prolongation of survival of ipilimumab-
treated patients. Investigations continue to further clarify 
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the role of ALC as an on-treatment pharmacodynamic 
marker of ipilimumab activity. However, biomarkers to 
select upfront the right patients for ipilimumab use are 
still missing. The identification of an immunological bio-
marker during the development of the anti PD-1 inhibi-
tor nivolumab [30, 31] and the subsequent validation of 
PD-L1 expression in the course of the pivotal phase III 
trials [2, 32–34] documents the potential and usefulness 
of such an approach. Ultimately, melanoma patients are 
expected to further benefit from a combination of such 
immunological treatment approaches, administered 
either sequentially [2, 4, 5] or concomitantly [35]. Fur-
thermore, two PD-1 inhibitors, pembrolizumab [34] and 
nivolumab [33], as well as the combination of nivolumab 
and ipilimumab have been shown to improve the pro-
gression-free [33, 34] and overall survival [34] compared 
with ipilimumab in phase 3 clinical trials in patients with 
metastatic melanoma.
Similar to previous studies of ipilimumab at a dose of 
3 mg/kg [6, 36] immune-related dermatological AEs, i.e. 
pruritus and rash, and immune-related gastrointesti-
nal AEs, i.e. diarrhea and colitis were the most frequent 
treatment-related adverse events. The rate of grade 3 and 
4 treatment-related AEs in patients with cutaneous mel-
anoma were in line with the results of the pivotal phase 
III trial of ipilimumab [6]. Most of the irAEs were revers-
ible when managed as per protocol-specific treatment 
guidelines and resolved with systemic glucocorticos-
teroid therapy. No new and unexpected safety findings 
were noted except one death with unknown cause was 
reported and the causal relationship to ipilimumab could 
not be excluded as per investigator.
Our phase II trial was limited by several factors; (1) the 
single-arm, non-randomized phase II design, however, at 
the time of study enrollment, no clear standard therapy 
for pretreated metastatic melanoma, especially for met-
astatic mucosal melanoma existed, (2) the small sample 
sizes of patients with mucosal and occult melanoma, (3) 
the lack of central review of imaging studies, and (4) the 
missing classification of tumor assessments according to 
immune-related response criteria [37].
Conclusions
In conclusion, ipilimumab is a treatment option for 
patients with advanced cutaneous melanoma seen in 
daily routine. Given the small number of patients with 
metastatic mucosal and occult melanoma, it is not possi-
ble to determine whether ipilimumab has activity in these 
melanoma subgroups. The ALC at week 4 appears to be 
an early biomarker of response and need further confir-
mation in randomized controlled trials. Immune-related 
AEs were manageable and reversible in most of the cases.
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